Search results
Results from the WOW.Com Content Network
0.5–5 mg/day Various: Estrogen: SC implant: 50–200 mg every 6–24 mos Estradiol valerate: Progynova: Estrogen: Oral: 2–10 mg/day Progynova: Estrogen: Sublingual: 1–8 mg/day Delestrogen [c] Estrogen: IM, SC: 2–10 mg/wk or 5–20 mg every 2 wks Estradiol cypionate: Depo-Estradiol: Estrogen: IM, SC: 2–10 mg/wk or 5–20 mg every 2 wks ...
Cyproterone acetate (CPA), sold alone under the brand name Androcur or with ethinylestradiol under the brand names Diane or Diane-35 among others, is an antiandrogen and progestin medication used in the treatment of androgen-dependent conditions such as acne, excessive body hair growth, early puberty, and prostate cancer, as a component of feminizing hormone therapy for transgender individuals ...
0.5 mg/day: 1–1.5 mg/day: 2–3 mg/day Vaginal: Estradiol: 25 μg/day – – Estriol: 30 μg/day: 0.5 mg 2x/week: 0.5 mg/day IM Tooltip Intramuscular or SC injection: Estradiol valerate – – 4 mg 1x/4 weeks Estradiol cypionate: 1 mg 1x/3–4 weeks: 3 mg 1x/3–4 weeks: 5 mg 1x/3–4 weeks Estradiol benzoate: 0.5 mg 1x/week: 1 mg 1x/week ...
>1 mg/day: 1.27 (1.16–1.39)* 1.22 (1.09–1.37)* 1.35 (1.18–1.55)* Conjugated estrogens alone ≤0.625 mg/day >0.625 mg/day: 1.49 (1.39–1.60)* 1.40 (1.28–1.53)* 1.71 (1.51–1.93)* Estradiol/medroxyprogesterone acetate: 1.44 (1.09–1.89)* Estradiol/dydrogesterone ≤1 mg/day E2 >1 mg/day E2: 1.18 (0.98–1.42) 1.12 (0.90–1.40) 1.34 ...
[126] [127] [124] Women who are not on a birth control pill or hormone therapy have a risk of VTE of about 1 to 5 out of 10,000 women per year. [ 126 ] [ 127 ] [ 116 ] [ 124 ] In women taking a birth control pill containing ethinylestradiol and a progestin, the risk of VTE is in the range of 3 to 10 out of 10,000 women per year.
Estradiol and norethisterone acetate (Activella, Amabelz) – 1 mg / 0.5 mg; 0.5 mg / 0.1 mg Ethinylestradiol and norethisterone acetate (FemHRT) – 25 μg / 0.5 mg Estradiol/progesterone (TX-001HR), a combination of estradiol and progesterone in oil-filled capsules, is currently pending approval.
Other research has found that the rate of VTE is 1 to 5 in 10,000 woman-years in women who are not pregnant or taking a birth control pill, 3 to 9 in 10,000 woman-years in women who are on a birth control pill, 5 to 20 in 10,000 women-years in pregnant women, and 40 to 65 in 10,000 women-years in postpartum women. [104]
Conversely, the incidences of fatigue and amenorrhea were significantly greater in the Diane plus Androcur group relative to the Diane alone group (6.7% vs. 2.5% and 5.4–32.6% vs. 0–4.2%, respectively), the incidence of breast tenderness was significantly lower in the Diane plus Androcur group than in the Diane alone group (3.6–26.3% vs ...